Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The injectable hormone was approved to treat excess abdominal fat in those with antiretrovira-associated lipodystrophy.
A long-term study also found that superinfection—acquiring a second strain of HIV—was not a risk for the transplantees.
An NIH-sponsored peer-recruitment study is part of a larger push to figure out how to drive up the viral suppression rate in the U.S.
The program was associated with an impressive rise in viral suppression rates.
The Mosaico study will enroll gay and bisexual men and transgender people at significant risk for the virus.
The viral suppression rate in this group was considerably higher than that seen in the same clinics a decade before.
The largest-ever HIV prevention study found that door-to-door HIV testing, with linkage to treatment, lowered infection rates.
Because the scientists use fetal tissue.
The newly released PARTNER2 study documented 77,000 condomless anal sex acts between mixed-HIV-status men; Opposites Attract had 12,000.
NIH researchers have prompted animals to develop broadly neutralizing antibodies against the virus; an early human trial is in the works.
This NIH study closely monitored 10 people with HIV who stopped antiretroviral treatment for weeks to months in a larger cure study.
A trial of long-acting cabotegravir injected every eight weeks is already under way among men who have sex with men and trans women.
Although we have the tools to end the epidemic through treatment and PrEP, costs and other considerations limit these methods.
Here’s how you can take action to support rectal microbicide research.
Highlights from the research presented at the 9th International AIDS Society Conference on HIV Science in Paris.
The vaccine prompted a robust immune response against HIV in those without the virus; now researchers hope to move it into advanced trials.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.